Presenter Joseph R. Mikhael MD, MEd, FRCPC, FACP Professor of Medicine Mayo College of Medicine Associate Dean Mayo School of Graduate Medical Education Deputy Director - Education Mayo Clinic Cancer Center Phoenix, AZ Additional Content Development Faculty Saad Z. Usmani, MD, FACP Chief, Plasma Cell Disorders Director, Clinical Research in Hematologic Malignancies Clinical Professor of Medicine UNC-Chapel Hill School of Medicine Department of Hematologic Oncology & Blood Disorders Levine Cancer Institute/ Carolinas HealthCare System Charlotte, NC
Ajai Chari, MD, PhD
Associate Professor of Medicine Division of Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai New York, NY
The treatment landscape for multiple myeloma (MM) is rapidly evolving. This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma.
. Target Audience
Community medical oncologists, radiation oncologists, hematologists, hematologist/oncologists, internists, oncology nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians involved in the management of patients with MM.
Upon completion of this educational activity, the participant should be able to:
Discuss new treatment options stemming from recent FDA approvals in the relapsed/refractory setting.
Review recently published clinical trial data on the efficacy and safety of emerging treatments for relapsed/refractory patients.
Describe recent changes to clinical practice guidelines affecting care for patients with relapsed/refractory disease.
Summarize best practices with respect to communication and coordination among members of the multidisciplinary myeloma care team.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Dr. Mikhael has disclosed the following:
Research Grant: AbbVie, Celgene, Sanofi
Dr. Usmani has disclosed the following:
Speakers Bureau: Amgen, Celgene, Takeda
Consultant/Advisor: Amgen, Celgene, Janssen, SkylineDX
Research Grant: Amgen, Celgene, Janssen, Takeda, Sanofi, Array BioPharma
Dr. Chari has disclosed the following:
Consultant/Advisor: Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen Novartis, Millennium, Amgen
Research Grant: Array BioPharma, Celgene, Janssen, Novartis, Millennium, Onyx, Pharmacyclics
Penn State staff involved in the development and review of this activity have nothing to disclose.
MCM Education staff involved in the development and review of this activity have nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Commercial Support Statements
Supported by independent educational grants from Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; or Takeda Oncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.